Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
Nearly half of those who have it reside in the Southern U.S.
Medical advances have stopped HIV from being a death sentence.
One price watchdog group says no.
The FDA approved Gilead's novel cancer-fighting gene therapy.
The price of the drug, which is to be administered just once to each patient, will be $373,000.